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Introduction
• Radiation therapy is used independently or
in combination with other oncology
modalities to treat or relieve symptoms of
cancer patients. High-intensity radiation
interacts with the tumor while sparing
healthy tissue.
• Depending on tumor location, life
expectancy, and severity of symptoms, the
oncology team must coordinate this
information into treatment planning.
• Those with terminal cancer have
decreasing end-of-life qualities. The goal of
radiation therapy then becomes symptom
relief rather than cancer treatment and
survival. (Bussman-Yeakel, 2016, p. 480)

What is Palliative Radiotherapy?
• Palliative radiotherapy practices are widely utilized in
30-40% of all cancer treatments (Huynh & Spektor,
2019, p. 326)

• Quality of life can be increased with the proper use
of palliative radiotherapy
• If used properly, can achieve:
• Decreased symptoms
• Decreased hospitalizations
• A preferred environment at the time of
death
• Avoiding end-of-life chemotherapy
treatments
• Access to strong opioids
• Those who receive palliative
radiotherapy are 2x more
likely to have access than
those who refuse palliative
radiotherapy (Ziegler et al.,
2017, p. 7).
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The Key: Timing and Fractioniation

In the Future

• Studies have found that the “association between
longer interval[s] from first contact with palliative
care to death” results in increased end-of-life
qualities (Ziegler et al., 2018, p.8)
• If palliative care is not administered
until the last four weeks of life, it will
not be as effective compared to those
who have undergone palliative
radiotherapy for a longer period

• Few studies have been conducted to evaluate
how to maximize effectiveness of palliative
radiotherapy.
• Multiple articles have found that
earlier and proper diagnosis by
physicians is crucial.
• Advanced technologies are being used to further
assess prognosis. The use of biomarkers is a
non-invasive way to determine biological changes
(responsiveness) throughout treatment as well as
tumor relapse. (Huynh & Spektor, 2019, p. 332)

(Ziegler et al, 2018, p. 8)

• The earlier the stage at diagnosis, the
sooner palliative radiotherapy can be
deemed necessary and administered.
• A treatment’s effects with more dose per fraction
for less fractions are found to be relieved two
weeks quicker than a treatment with less dose per
fraction for more fractions (Støchkel Frank et al.,
2018, p. 6)

• This results in relief of symptoms with
high dose and low toxicity.

Determining a Guideline
• Performance status (PS) has been found to be the
“predominant prognostic factor and a significant
predictor for futile radiotherapy at the end of life”
(Støchkel Frank et al., 2018, p. 2)

Image of a linear accelerator used for patients with
external beam radiation therapy treatments (BussmanYeakel, 2016)

Cancer Severity
Stage 0

Stage 1
Stage 2

Stage 3

Stage 4

Abnormal cells begin to
form but are not or
minimally detected.
Localized tumor with no
additional spread.
Tumor has grown to a
size less than 5 cm.
Lymph nodes start to
become effected.
Tumor has grown to a
size larger than 5 cm.
Spreads into deeper
structures.
Cancer has
metastasized to other
areas of the body.

(Bussman-Yeakel, 2016, p. 483)

• Those with better performance status
results in longer survival after treatment
when given fractionalized palliative
radiotherapy compared to those with
worse performance status.
• Palliative radiotherapy may be futile in types of
cancer that only show symptoms in a later stage. This
causes the diagnosis to be delayed, thus pushing off
appropriate treatment.
• This includes metastasized cancers with
multiple lesions throughout the body.
• The microenvironments of the cancer site must be
considered when planning.
o In lower dose palliative radiotherapy, there is
preserved vasculature which allows the tumor to
start reconstructing to normal tissue characteristics.
In higher doses, there is overall tumor ablation
which results in programmed vasculature cell
death.
• Fibroblastic microenvironments
require a higher dose per fraction to
speed up the radiation response.
(Huynh & Spektor, 2019, pp. 328-329)

Images show a single-fraction treatment plan for a breast
cancer patient with bone metastases. Picture B & D can be
compared to show the response after treatment.
(Loi, Nuyttens, Desideri, Greto, & Livi, 2019)

Conclusion

• Graph showing the correlation between time from
prescription of palliative radiotherapy to death with
chance of survival.
• Colored lines represent the PS of patients undergoing
palliative radiotherapy. The difference between PS 2 and
PS 3-4 was not statistically significant. Those with a PS
of 2 or more were found to have less time of survival
throughout treatment compared to those with better PS.
This graph shows that when diagnosis and palliative
treatment is delayed, action becomes futile and there is
no benefit against terminal cancer effects.
(Støchkel Frank et al., 2018)

• Palliative radiotherapy is only effective when
planned and administered appropriately. It is
important for the radiation therapy team to have a
dialogue about treatment plans for each individual
patient. Those with advanced cancer and
developed symptoms need higher doses at less
fractions to feel quicker relief than those with less
severe symptoms for the same type of cancer.
• It is important to assess PS when determining the
prescription. The timing of palliative radiotherapy
is crucial for positive effects to occur in the
patient. Palliative radiotherapy is futile with near
end-of-life prognoses because of delayed
treatment. Instead, these patients should be
given supportive care or hospice services (Puckett,
Luitweiler, Potters, & Teckie, 2017, p. 788).
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